NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $32.48 -1.65 (-4.82%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AtriCure alerts:Sign Up Key Stats Today's Range$31.54▼$33.4850-Day Range$31.83▼$42.4052-Week Range$18.94▼$43.11Volume92,337 shsAverage Volume672,210 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$49.44Consensus RatingBuy Company OverviewAtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More… Remove Ads AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 68% of companies evaluated by MarketBeat, and ranked 316th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.59% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 19.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.59% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 19.72%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.11 News SentimentAtriCure has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for AtriCure this week, compared to 4 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,532.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Stock News HeadlinesAtriCure, Inc. (NASDAQ:ATRC) Director Karen Prange Sells 6,100 SharesMarch 8, 2025 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Sees Large Growth in Short InterestApril 3 at 2:05 AM | americanbankingnews.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 3, 2025 | Porter & Company (Ad)Canaccord Genuity Group Has Lowered Expectations for AtriCure (NASDAQ:ATRC) Stock PriceMarch 30, 2025 | americanbankingnews.comAtriCure's (ATRC) "Buy" Rating Reiterated at Needham & Company LLCMarch 30, 2025 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Trading Down 6.8% After Analyst DowngradeMarch 29, 2025 | americanbankingnews.comJPMorgan Chase & Co. Lowers AtriCure (NASDAQ:ATRC) Price Target to $46.00March 29, 2025 | americanbankingnews.comAtriCure price target raised to $58 from $57 at BTIGMarch 29, 2025 | markets.businessinsider.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $30.56 at the beginning of the year. Since then, ATRC shares have increased by 6.3% and is now trading at $32.4850. View the best growth stocks for 2025 here. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) posted its earnings results on Tuesday, October, 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. The firm's revenue for the quarter was up 17.9% on a year-over-year basis. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings10/29/2024Today4/03/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,300Year Founded2000Price Target and Rating Average Stock Price Target$49.44 High Stock Price Target$60.00 Low Stock Price Target$40.00 Potential Upside/Downside+50.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,700,000.00 Net Margins-9.61% Pretax Margin-9.39% Return on Equity-6.80% Return on Assets-5.19% Debt Debt-to-Equity Ratio0.13 Current Ratio3.65 Quick Ratio2.62 Sales & Book Value Annual Sales$465.31 million Price / Sales3.45 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book3.48Miscellaneous Outstanding Shares48,880,000Free Float47,316,000Market Cap$1.61 billion OptionableOptionable Beta1.53 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ATRC) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.